Alcyone Lifesciences To Present on Precision Therapy Delivery Technologies for Antisense Oligonucleotide and Gene Therapy at the 2019 Oligonucleotide Discovery and Delivery Conference.

LOWELL, Mass., March 25, 2019 /PRNewswire/ --Alcyone Lifesciences, Inc., a leader in transforming Disease Modifying Therapies for the Central Nervous System (CNS) and Oncology through its Advanced Precision Delivery Platforms, announced a presentation on its advanced precision therapy delivery platform for Antisense Oligonucleotide (ASO) and Gene Therapy at the 2019 Oligonucleotide Discovery and Delivery Conference.